7,648.50

+34.50

+0.45%

52,088.00

+170.00

+0.33%

28,779.50

+245.50

+0.86%

Russell 2000 Futures

2,836.40

+15.10

+0.54%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,917.60

+18.70

+0.48%

78,037.68

+179.09

+0.23%

Crude Oil Dec 26

100.64

-3.48

-3.34%

US Private Equity

10,850.63

-82.20

-0.75%

HKSE - Delayed Quote HKD

BeOne Medicines AG (6160.HK)

220.600 -0.800 (-0.36%)

As of 2:25:25 PM GMT+8. Market Open.

Loading Chart for 6160.HK

Chart Range Bar

Interval:

In partnership with ChartIQ

3 Healthcare Stocks To Watch In October 2026

3 Healthcare Stocks To Watch In October 2026

BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative

BeOne Medicines (ONC) Could Be 13% Undervalued As ESMO Data Lifts The Narrative

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong Buy

New Strong Buy Stocks for October 15th

New Strong Buy Stocks for October 15th

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

Biotech Leader BeOne Medicines Poised To Hit Early Buy Points

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run

Mobilize your Website

View Site in Mobile | Classic

Share by: